Head to Head Review: Elutia (NASDAQ:ELUT) versus enGene (NASDAQ:ENGN)

enGene (NASDAQ:ENGN) and Elutia (NASDAQ:ELUT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, institutional ownership, profitability, earnings and risk.

Profitability

This table compares enGene and Elutia’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-16.69%	-14.27%
Elutia	-218.72%	N/A	-142.61%

Valuation and Earnings

This table compares enGene and Elutia”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$55.14 million	($1.52)	-2.63
Elutia	$24.38 million	3.63	-$37.66 million	($2.47)	-0.88

Elutia has higher revenue and earnings than enGene. enGene is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for enGene and Elutia, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	0	1	8	1	3.00
Elutia	0	0	2	0	3.00

enGene presently has a consensus price target of $25.22, suggesting a potential upside of 530.56%. Elutia has a consensus price target of $9.00, suggesting a potential upside of 314.75%. Given enGene’s higher probable upside, equities research analysts plainly believe enGene is more favorable than Elutia.

Volatility and Risk

enGene has a beta of -0.38, suggesting that its share price is 138% less volatile than the S&P 500. Comparatively, Elutia has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500.

Institutional and Insider Ownership

64.2% of enGene shares are owned by institutional investors. Comparatively, 74.0% of Elutia shares are owned by institutional investors. 13.7% of enGene shares are owned by insiders. Comparatively, 40.8% of Elutia shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Elutia beats enGene on 7 of the 13 factors compared between the two stocks.

About enGene

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

About Elutia

Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.